Interphex Focuses on Counterfeit Prevention - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Interphex Focuses on Counterfeit Prevention
Interphex provided an opportunity to examine the latest pharmaceutical packaging concepts and packaging machines.


Pharmaceutical Technology



Hallie Forcinio
Anticounterfeiting measures ranked as a top-of-mind concern at this year's Interphex trade show, held March 21–23 in New York City. This matter is no surprise because incidents involving counterfeit drugs have spiked in recent years. As a result, manufacturers are taking steps to protect consumers and their brands, and the US Food and Drug Administration and several states are studying ways to tighten the supply chain.

As always, Interphex offered a great chance to study new pharmaceutical packaging concepts and packaging machines such as those designed to thwart counterfeiting, to protect against moisture and oxygen exposure, and to improve distribution.

Counterfeit prevention

Anticounterfeiting measures can be divided into two categories: overt and covert. Overt measures include color-shifting inks, optically variable devices, holograms, thermochromic ink or glue, and tamper-evident security seals. Covert measures include taggants and biomolecular markers, digital watermarks, microprinting, invisible graphics printed with UV- or IR-sensitive ink, antitheft devices, and security substrates. Coding schemas such as mass serialization and consecutive numbering also play a role. Experts recommend using a combination of features to achieve the best protection against counterfeiting.


Laser coder from ATS Automation Tooling Systems and proprietary ribbon from Tesa Tape, Inc. produces indelible, high-contrast codes on glass vials.
Multilayer approaches. Optically variable devices include an assortment of sophisticated technologies that can be combined to provide multifaceted protection. Some are readily visible, whereas others require a tool such as a magnifier or screened piece of film to detect. Examples include color effects, minitext, color flips, hidden information or features, image flips, nanotext or nanoimage, lens effects, rainbows, and grayscale images ("Trustseal," Kurz Transfer Products, Charlotte, NC, http://www.kurz.de/).

For labels, a multilayer approach includes adhesive colorants, tinting agents, marker dyes, color-shifting pigments, magnetic microwire, and proprietary markers (secure label solutions, Acucote, Inc., Graham, NC, http://www.acucote.com/).

Precisely positioned nanoclusters of metal particles on a highly reflective substrate make it possible to produce two- or three-phase color-shift labels that offer visible and machine-readable color shifts that are exclusive to a product or company. The metal clusters modify light waves as they enter the film. Optics within the film further alter the light as waves bounce back from a reflective layer ("Color Spectra," DuPont, Wilmington, DE, http://www2.dupont.com/packaging/en_US).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here